This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Marietta,
Georgia30060

Purpose:

The purpose of this study is to determine whether telavancin (TD-6424, ARBELIC) can be
safety administered to patients with bloodstream infections and whether telavancin is
effective in treating these infections.

Criteria:

Inclusion Criteria
- Documented S. aureus bacteremia
Exclusion Criteria
- Patients who had received or would have received more than 72 hours of potentially
effective systemic antistaphylococcal therapy within 7 days prior to randomization. The
following agents were considered potentially effective antistaphylococcal therapy:
antistaphylococcal penicillins (including nafcillin, oxacillin, or cloxacillin),
cephalosporins, fluoroquinolones, glycopeptides (including vancomycin and teicoplanin) and
linezolid

NCT ID:

NCT00062647

Primary Contact:

Principal InvestigatorG. Ralph Corey, MDDuke University

Backup Contact:

N/A

Location Contact:

Marietta, Georgia 30060United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: December 13, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.